Ipsen and Biomunex enter agreement for cancer therapy

Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals to develop BMX-502.

Related Posts

STAT+: The biotech scorecard for the fourth quarter: 16...

Oct 2, 2023

US FDA accepts Satsuma’s 505(b)(2) NDA for STS101

May 20, 2023

NHS launches “game-changer” and lifesaving anti-smoking...

Nov 13, 2024